Urinary incontinence
Drug research and approvals for urinary incontinence: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 174 studies of urinary incontinence are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 174
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 3
- rTMS for Incontinence After Prostate TreatmentNCT07948330 · Not applicable · The Methodist Hospital Research Institute · starts Sep 16, 2026
- Peroneal Transcutaneous Neuromodulation in Children With Overactive BladderNCT07939061 · Not applicable · General University Hospital, Prague · starts Sep 3, 2026
- A Study to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or…NCT07932925 · Phase 3 · Pfizer · starts Nov 17, 2026
- Standardized 4D Transperineal Ultrasound Assessment of Urethrovesical Junction Mobility After Vaginal Laser Treatment…NCT07907016 · Not reported · Charles University, Czech Republic · starts Jan 1, 2027
- Effectiveness of Individualized Pelvic Floor Muscle Rehabilitation in Addition to Standard Urotherapy and Alarm Therapy…NCT07890194 · Not applicable · Hacettepe University · starts Aug 31, 2026
- Motor Imagery-Assisted Pelvic Floor Muscle Training for Stress Urinary Incontinence in Postmenopausal WomenNCT07853755 · Not applicable · Istanbul Medipol University Hospital · starts Sep 28, 2026
- Tractography-Guided Nerve-Sparing in Prostate CancerNCT07847385 · Not applicable · Massimo Valerio · starts Sep 1, 2026
- DEVELOPMENT AND VALIDATION OF THE URINARY INCONTINENCE KINESIOPHOBIA SEVERITY SCALENCT07842575 · Not reported · Ahi Evran University Education and Research Hospital · starts Sep 1, 2026
- Effectiveness of an 8-week Independent Cadence Retraining Program on Stress Urinary Incontinence in Parous Runners.NCT07829692 · Not applicable · Mayo Clinic · starts Aug 5, 2026
Approved 11
- TolterodineMuscarinic acetylcholine receptor M3 antagonist
- OxybutyninMuscarinic acetylcholine receptor M3 antagonist
- SolifenacinMuscarinic acetylcholine receptor M3 antagonist
- MirabegronBeta-3 adrenergic receptor agonist
- DarifenacinMuscarinic acetylcholine receptor M3 antagonist
- FesoterodineMuscarinic acetylcholine receptor M3 antagonist
- TrospiumMuscarinic acetylcholine receptor M3 antagonist
- TerodilineMuscarinic acetylcholine receptor antagonist
- VibegronBeta-3 adrenergic receptor agonist
- Propiverine
- Emepronium
Phase 3 5
- DuloxetineSerotonin transporter inhibitor
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Dimethyl sulfoxide
- Iltamiocel
- ImidafenacinMuscarinic acetylcholine receptor M3 antagonist
Phase 2 5
- EsreboxetineNorepinephrine transporter inhibitor
- LidocaineSodium channel alpha subunit blocker
- TaranabantCannabinoid CB1 receptor inverse agonist
- FlavoxatePhosphodiesterase 4 inhibitor
- Meladrazine
Phase 1 or earlier 4
- PilocarpineMuscarinic acetylcholine receptor M3 agonist
- SildenafilPhosphodiesterase 5A inhibitor
- MethoxamineAdrenergic receptor alpha-1 agonist
- Litoxetine
How its trials ended
1,283 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 218 whose ending is known, 47% met their primary endpoint, 5% missed it and 48% stopped early.
- Completed, result not reported63950%
- Ongoing23118%
- Status unknown19515%
- Met its primary endpoint1038%
- Stopped: other or unclear655%
- Stopped: enrollment or feasibility242%
- Missed its primary endpoint111%
- Stopped: sponsor or business decision6<1%
- Stopped: lack of efficacy5<1%
- Stopped: safety2<1%
- Stopped: funding2<1%
| Aug 17, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of berobenatide in adult female participants with stress…Berobenatide (PF-08653944, MET097) | Pfizer | Pending |
| Mar 17, 2026 | A pilot randomized trial: the effect of local androgenotherapy combined with pelvic floor muscle training on sui in womenPrasterone | Ciusss De L'Estrie - Centre Hospitalier Universitaire De Sherbrooke | Pending |
| Sep 12, 2025 | A master protocol to investigate the efficacy and safety of orforglipron tablet once daily compared with placebo in female participants with stress urinary…Orforglipron (LY3502970) | Eli Lilly | Ongoing |
| Oct 5, 2018 | A phase 2, multicenter, randomized, double-blind, placebo-controlled, single-treatment, 2-stage, dose-finding study evaluating the efficacy and safety of botox…Botox | AbbVie | Closed |
| Jan 27, 2017 | A double-blind, randomised, placebo-controlled, parallel-group, phase II, dose-ranging trial to evaluate the efficacy, safety, and tolerability of oral…Litoxetine | Ixaltis | Closed |
| May 7, 2014 | Botox in the treatment of urinary incontinence due to overactive bladder in patients 12 to 17 years of ageBotox (onabotulinum) | AbbVie | Ongoing |
| Dec 16, 2013 | Botox in the treatment of urinary incontinence due to neurogenic detrusor overactivity in patients 8 to 17 years of ageBotox (onabotulinumtoxina for injection) | AbbVie | Ongoing |
| Oct 22, 2004 | EmselexDarifenacin hydrobromide | pharmaand GmbH | EMA ↗ |
| Aug 11, 2004 | YentreveDuloxetine | Eli Lilly Nederland B.V. | EMA ↗ |
| Jun 15, 2004 | Kentera (previously Oxybutynin Nicobrand)Oxybutynin | Teva B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA